WO2002043566A3 - Devices and methods for treating low blood sugar levels - Google Patents

Devices and methods for treating low blood sugar levels Download PDF

Info

Publication number
WO2002043566A3
WO2002043566A3 PCT/US2001/044552 US0144552W WO0243566A3 WO 2002043566 A3 WO2002043566 A3 WO 2002043566A3 US 0144552 W US0144552 W US 0144552W WO 0243566 A3 WO0243566 A3 WO 0243566A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
source
area
intact skin
devices
Prior art date
Application number
PCT/US2001/044552
Other languages
French (fr)
Other versions
WO2002043566A2 (en
Inventor
Martin G Baum
Roger T Putman
Original Assignee
Martin G Baum
Roger T Putman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martin G Baum, Roger T Putman filed Critical Martin G Baum
Priority to AU2002230509A priority Critical patent/AU2002230509A1/en
Publication of WO2002043566A2 publication Critical patent/WO2002043566A2/en
Publication of WO2002043566A3 publication Critical patent/WO2002043566A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Abstract

The present invention relates to methods and devices employed to control the onset of blood sugar levels below a predetermined minimum level over an extended period of time. The invention includes methods and devices for producing a therapeutic effect in a subject including placing a source of glucose or glucagon in a transdermal patch in transmitting relationship to an area of intact skin; and administering glucose or glucagon to the subject from the source through the area of intact skin for an extended period of time at a therapeutically effective rate for a substantial portion of the extended period of time to prevent the onset of a low blood sugar level in the subject. The methods and devices may include administering glucose or glucagon to the subject from the source through the area of intact skin for at least 4 hours, or longer, perhaps 24 hours or more, and are particularly well suited for administering glucose or glucagon to the subject from the source through the area of intact skin between usual sleeping hours. Additional therapeutic substances may also be administered to the subject from the source through the area of intact skin, including one or more nutritional supplements such as vitamins A, C, or D.
PCT/US2001/044552 2000-11-28 2001-11-28 Devices and methods for treating low blood sugar levels WO2002043566A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002230509A AU2002230509A1 (en) 2000-11-28 2001-11-28 Devices and methods for treating low blood sugar levels

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72383700A 2000-11-28 2000-11-28
US09/723,837 2000-11-28

Publications (2)

Publication Number Publication Date
WO2002043566A2 WO2002043566A2 (en) 2002-06-06
WO2002043566A3 true WO2002043566A3 (en) 2002-09-26

Family

ID=24907892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044552 WO2002043566A2 (en) 2000-11-28 2001-11-28 Devices and methods for treating low blood sugar levels

Country Status (2)

Country Link
AU (1) AU2002230509A1 (en)
WO (1) WO2002043566A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
MXPA05006994A (en) 2002-12-27 2005-10-18 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia.
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US9452258B2 (en) 2007-10-09 2016-09-27 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
EP4250312A3 (en) 2007-10-25 2023-11-01 DexCom, Inc. Systems and methods for processing sensor data

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5360614A (en) * 1993-04-26 1994-11-01 The Estee Corporation Method of controlling the release of carbohydrates by encapsulation and composition therefor
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5360614A (en) * 1993-04-26 1994-11-01 The Estee Corporation Method of controlling the release of carbohydrates by encapsulation and composition therefor
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides

Also Published As

Publication number Publication date
AU2002230509A1 (en) 2002-06-11
WO2002043566A2 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
IL135712A0 (en) Methods for treating hypercoagulable states or acquired protein c deficiency
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
JP2003521528A5 (en)
WO2002065985A3 (en) Methods of treating diabetes mellitus
DE60222137D1 (en) SUGAR DERIVATIVES OF HYDROMORPHONE, DIHYDROMORPHINE AND DIHYDROISOMORPHINE, COMPOSITIONS THEREOF AND USE FOR THE PREVENTION AND TREATMENT OF PAIN
WO2004052284A3 (en) Treatment of diabetes
WO2003089033A8 (en) Implantable drug delivery system responsive to intra-cardiac pressure
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
EP1733734A3 (en) Placental alkaline phosphatase to control diabetes
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2002060410A3 (en) Methods for sustained release local delivery of drugs for ablation of unwanted tissue
WO2004010946A3 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
WO2005087255A3 (en) Method of optimizing treatment with interferon-tau
WO2002043566A3 (en) Devices and methods for treating low blood sugar levels
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein
WO1994024279A3 (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
NO20005131L (en) New treatments for nervous disorders
WO2001028578A3 (en) A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
FR2786699B1 (en) MEDICINE, IN PARTICULAR FOR PREVENTING OR TREATING SEXUAL DYSFUNCTIONS
WO2003082283A3 (en) Pharmaceutical composition with combined active agents and methods for using the same
CA2405265A1 (en) Method of preventing or treating diabetes
WO2004024168A8 (en) Composition and method for use in intestinal cleansing procedures
DE60120371D1 (en) USING GROWTH HORMONE IN LESS BOXES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP